BriaCell Announces Presentation at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
September 09, 2024 07:50 ET
|
BriaCell Therapeutics Corp.
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 09, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...
Intuitive Machines Announces Key Leadership Appointments
September 09, 2024 07:45 ET
|
Intuitive Machines, LLC
HOUSTON, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Intuitive Machines, Inc. (Nasdaq: LUNR, LUNRW) (“Intuitive Machines”) (“Company”), a leading space exploration, infrastructure, and services company,...
Progress Software to Report Third Quarter 2024 Financial Results on September 24, 2024
September 09, 2024 07:31 ET
|
Progress Software Corporation
Progress announces financial results for its fiscal third quarter of 2024
Cytokinetics Announces Data From Phase 1 Study of CK-4021586
September 09, 2024 07:30 ET
|
Cytokinetics, Incorporated
Phase 2 Clinical Trial in Patients with Heart Failure with Preserved Ejection Fraction Expected to Begin in Q4 2024 SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cytokinetics,...
NIP Group Inc. Enters Game Publishing Market, Expanding Digital Entertainment Ecosystem
September 09, 2024 07:30 ET
|
NIP GROUP INC.
Esports Powerhouse Diversifies into Game Development Industry Veteran Allen Sui to Lead New Venture SHENZHEN, China, Sept. 09, 2024 (GLOBE NEWSWIRE) -- NIP Group Inc. (NASDAQ: NIPG) (the “Company”...
Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting
September 09, 2024 07:30 ET
|
Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that new supported and/or funded research on the clinical impact of...
FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study
September 09, 2024 07:30 ET
|
Rezolute, Inc.
REDWOOD CITY, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company developing a novel therapy to treat...
Psyence Biomed Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care
September 09, 2024 07:30 ET
|
Psyence Biomedical Ltd.
NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”), a developer of naturally derived psilocybin-based therapeutics, today...
Theratechnologies fera des présentations aux conférences d'investisseurs en septembre
September 09, 2024 07:30 ET
|
Theratechnologies
MONTRÉAL, 09 sept. 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une entreprise biopharmaceutique axée sur la mise au...
Theratechnologies to Present at Upcoming Investor Conferences in September
September 09, 2024 07:30 ET
|
Theratechnologies
MONTREAL, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and...